|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis显示文摘 | Katrin M Sjoquist Bryan H Burmeister B Mark Smithers John R Zalcberg R John Simes Andrew Barbour Val Gebski | 2011 | Lancet Oncology2011，，7： | 4 |
| 2 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 3 | Personalising pancreas cancer treatment:When tissue is the issue显示文摘The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX(fluorouracil,leucovorin,irinotecan and oxaliplatin)and nab-paclitaxelgemcitabine have demonstrated some improved outcomes.Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course.This has allowed identification of potentially actionable mutations that may be targeted by new biological agents.The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition.This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice. | Katrin M Sjoquist Venessa T Chin Lorraine A Chantrill Chelsie O'Connor Chris Hemmings David K Chang Angela Chou Marina Pajic Amber L Johns Adnan M Nagrial Andrew V Biankin Desmond Yip | 2014 | World Journal of Gastroenterology2014，20，24： | 2 |
| 4 | Arginase inhibition me diates cardioprotection during ischaemia-reperfusion 显示文摘 | Jung C Gonon AT Sjoquist PO etal | 2010 | Card- iovasc Res2010，85，： | 1 |
| 5 | Sur-vival after neoadjuvant chemotherapy or chemoradiotherapy for re-sectable oesophageal carcinoma : an updated meta-analysis 显示文摘 | SJOQUIST K M BURMEISTER B H SMITHERS B M | 2011 | Lancet Oncol2011，12，7： | 1 |
| 6 | Spatial mismatch and social acceptability显示文摘 | Sjoquist D L | 2001 | Jour- nal of Urban Economics2001，50，： | 1 |
| 7 | Pharmacokinetics of latanoprost in the cynomolgus monkey,3rd communication: tissue distribution after topical administration of the eye studies by whole body autoradiography 显示文摘 | Sjoquist B Johnasson A Stjernschantz J | 1999 | Arzneimittelforschung1999，49，： | 1 |
| 8 | Use of chicken antibodies in enzyme immunoassays to avoid interference by rheumatoid factors显示文摘 | Larsson A Karlsson - Parra A Sjoquist J | 1991 | Clin Chem1991，37，3： | 1 |
| 9 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated rneta+analysis显示文摘 | Sjoquist KM Burmeister BH Smithers BM | 2011 | Lancet Oncol2011，12，7： | 1 |
| 10 | Effects of angiotensin Ⅱ receptor blocker candesartan on myocardial ischemic/re-perfusion injury显示文摘 | Shimizu M Sjoquist PO Wang QD | | 0，，11： | 1 |
| 11 | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis显示文摘 | Sjoquist KM Burmeister BH Smithers BM | 2011 | The lancet oncology2011，12，7： | 1 |
| 12 | Towards a quantum Hall effect for atoms using electric fields 显示文摘 | Ericson M Sjoquist E | 2001 | Phys Rev A2001，65，01： | 1 |
| 13 | Pharmacologicalpossibilities for protection against myocardial reperfusioninjury显示文摘 | Wang QD Pernow J Sjoquist PO | 2002 | Cardiovase Res2002，55，1： | 1 |
| 14 | Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors显示文摘 | Pietras K Ostman A Sjoquist M | 2001 | Cancer Res2001，61，7： | 1 |
| 15 | Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery 显示文摘 | CAMP AS C B TORIS C B SJOQUIST B | 2004 | Ophthalmology2004，111，12： | 1 |
| 16 | Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort- acting calcium antagonist for rapid blood pressure control 显示文摘 | Nordlander M Sjoquist PO Ericsson H | 2004 | Cardiovasc Drug Rev2004，22，3： | 1 |
| 17 | Pharmacological possibilities for protection against myocardical reperfusion injury显示文摘 | Wang QD Pernow J Sjoquist PO | 2002 | Cardiovasc Res2002，55，1： | 1 |
| 18 | Pharmacodynamic, pharmacokinetic and clinical effects ofclevidipine, an ultrashort-acting calciumantagonist for rapid blood pressure control显示文摘 | NORD LANDER M SJOQUIST PO ERICSSON H | 2004 | Cardiovasc Drug Rev2004，22，3： | 1 |
| 19 | Myocardioprotective effects of felodipine in an antihypertensive dosage:an experimental study in pigs显示文摘 | Shimizu M Wang QD Sjoquist PO | 1998 | Cardioras Drugs Ther1998，12，1： | 1 |
| 20 | Survival afterneoadjuvant chemoradiotherapy or chemoradiotherapy for respectable oesophageal carcinoma: an updated meta- analysis显示文摘 | Sjoquist KM Burmeister BH Smithers BM | 2011 | LancetOncol2011，12，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员